Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received an average rating of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $8.50.
A number of research analysts have issued reports on SGMO shares. Cowen and Company reiterated a “buy” rating on shares of Sangamo Therapeutics in a research note on Wednesday, March 22nd. Jefferies Group LLC reiterated a “buy” rating and set a $17.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, June 22nd. ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. Finally, Wedbush reiterated a “neutral” rating and set a $4.00 price objective (down previously from $6.00) on shares of Sangamo Therapeutics in a research report on Tuesday, May 16th.
In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $10.00, for a total transaction of $150,000.00. Following the sale, the vice president now directly owns 35,517 shares in the company, valued at $355,170. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders have sold 19,639 shares of company stock worth $184,765. Company insiders own 8.10% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Fox Run Management L.L.C. bought a new stake in shares of Sangamo Therapeutics during the second quarter valued at about $126,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Sangamo Therapeutics by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 780 shares during the period. Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Sangamo Therapeutics during the first quarter valued at about $154,000. A.R.T. Advisors LLC bought a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at about $161,000. Finally, Bank of America Corp DE boosted its stake in shares of Sangamo Therapeutics by 49.9% in the first quarter. Bank of America Corp DE now owns 32,625 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 10,861 shares during the period. 59.24% of the stock is currently owned by institutional investors.
Shares of Sangamo Therapeutics (NASDAQ:SGMO) traded down 6.93% during trading on Friday, reaching $9.40. The company’s stock had a trading volume of 1,337,798 shares. The stock’s 50 day moving average price is $7.82 and its 200-day moving average price is $4.99. Sangamo Therapeutics has a 52-week low of $2.65 and a 52-week high of $10.50. The stock’s market cap is $676.23 million.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. The company had revenue of $3.40 million for the quarter, compared to analyst estimates of $4.14 million. Sangamo Therapeutics had a negative return on equity of 50.76% and a negative net margin of 380.44%. The firm’s revenue was down 12.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.23) earnings per share. Equities analysts anticipate that Sangamo Therapeutics will post ($0.93) EPS for the current year.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
What are top analysts saying about Sangamo Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sangamo Therapeutics Inc. and related companies.